# iShares Healthcare Innovation UCITS ETF (DRDR)

**Source:** https://fundology.uk/fund/drdr · ISIN IE00BYZK4776 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 30/09/2026, DRDR (iShares Healthcare Innovation UCITS ETF, ISIN IE00BYZK4776) closed at £8.24 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 30/09/2026 its total return was +11.0%, or −13.2% after UK CPIH inflation.

## Summary

iShares Healthcare Innovation UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2016. It tracks the iSTOXX FactSet Breakthrough Healthcare. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£8.24** (30/09/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | DRDR |
| ISIN | IE00BYZK4776 |
| Category | Technology |
| Type | ETF |
| Provider | iShares |
| Tracks | iSTOXX FactSet Breakthrough Healthcare |
| Income | Accumulating |
| Ongoing charge | 0.40% a year (£40 per £10,000) |
| Fund size | £852m |
| Launched | 2016 |
| Domicile | Ireland |

## Past returns (periods to 30/09/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +37.69% | +33.37% | income reinvested |
| 3 years | +49.24% | +34.67% | income reinvested |
| 5 years | +11.02% | -13.21% | income reinvested |

Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −14.9%, 2023 −2.5%, 2024 +2.7%, 2025 +10.8%; 2026 to 30/09/2026 +22.3%. Returns of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +39.3%; to 30/09/2025: −1.5%; to 30/09/2024: +8.2%; to 30/09/2023: −10.5%; to 30/09/2022: −18.7%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2022 | -14.9% | -22.1% | Price |
| 2023 | -2.5% | -6.4% | Price |
| 2024 | +2.7% | -0.8% | Price |
| 2025 | +10.8% | +7.0% | Price |
| 2026 to 30/09/2026 | +22.3% | +18.9% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 17.16% | -10.39% |
| 3 years | 16.55% | -20.57% |
| 5 years | 17.52% | -33.27% |

## Largest fall

Volatility of iShares Healthcare Innovation UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 17.2% over 1 year, 16.5% over 3 years, 17.5% over 5 years. Largest fall in the price of iShares Healthcare Innovation UCITS ETF since October 2021, in pounds: −33.3% from 05/11/2021 to 27/10/2023. The lowest 12-month return of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund) since January 2021 was −27.2% (12 months to 17/06/2022); the highest was +38.4% (12 months to 25/09/2026). On 30/09/2026 the price of iShares Healthcare Innovation UCITS ETF was at its highest weekly close since October 2021, in pounds.

## Charges compared with similar funds

Ongoing charge of iShares Healthcare Innovation UCITS ETF 0.40% a year, as of 01/10/2026: 74 of the 118 other technology funds charge more, 11 the same and 33 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.40%** per year
- ISA eligible: yes
- SIPP eligible: yes

## Top holdings

Largest positions (as of 29/09/2026):

| Holding | Weight |
|---|---|
| Moderna | 5.15% |
| Natera | 2.25% |
| Illumina | 2.05% |
| Iqvia | 1.74% |
| Revvity | 1.72% |
| Genmab | 1.71% |
| Guardant Health | 1.65% |
| Agilent Technologies | 1.56% |
| Roivant Sciences | 1.52% |
| Merck | 1.51% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed.

### By sector

As published by iShares, as of 29/09/2026.

| Sector | Weight |
|---|---|
| Health Care | 98.1% |
| Information Technology | 1.1% |
| Industrials | 0.4% |
| Cash and derivatives | 0.2% |
| Real Estate | 0.2% |

### By country

As published by iShares, as of 29/09/2026.

| Country | Weight |
|---|---|
| United States | 71.7% |
| Switzerland | 5.1% |
| Japan | 4.4% |
| South Korea | 3.6% |
| Denmark | 2.6% |
| Belgium | 2.4% |
| Germany | 1.8% |
| United Kingdom | 1.5% |
| Other countries | 6.8% |

### By type of asset

Added up from the holdings iShares publishes, as of 29/09/2026.

| Type of asset | Weight |
|---|---|
| Equity | 99.8% |
| Cash and money market | 0.4% |

All 199 holdings: https://fundology.uk/fund/drdr/holdings

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.